Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025
Calidi Biotherapeutics (NYSE: CLDI) announced the acceptance of its abstract for presentation at the AACR Annual Meeting in Chicago (April 25-30, 2025). The presentation, titled 'Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites,' will showcase data from their proprietary RTNova systemic platform.
The platform features a novel vaccinia virus strain enveloped with human cell membrane (extracellular enveloped virus or EEV), designed to target distant tumors while avoiding immune system elimination. This technology aims to address treatment challenges in advanced-stage metastatic cancers, particularly when intratumoral administration isn't feasible.
The company also plans to submit additional data about RTNova's lead clinical candidate selection at the ASCO Annual Meeting in June 2025. This development complements Calidi's existing clinical and preclinical work on localized and intratumoral cell-based virotherapies with SNV (SuperNova) and NNV (NeuroNova).
Calidi Biotherapeutics (NYSE: CLDI) ha annunciato l'accettazione del suo abstract per la presentazione al AACR Annual Meeting di Chicago (25-30 aprile 2025). La presentazione, intitolata 'Sviluppo di una Viroterapia Sistemica Avvolta per il Targeting di Tutti i Siti Metastatici', metterà in evidenza i dati della loro piattaforma proprietaria RTNova.
Questa piattaforma presenta un nuovo ceppo di virus vaccinia avvolto con membrana cellulare umana (virus avvolto extracellulare o EEV), progettato per colpire tumori distanti evitando l'eliminazione da parte del sistema immunitario. Questa tecnologia mira ad affrontare le sfide terapeutiche nei tumori metastatici in fase avanzata, in particolare quando l'amministrazione intratumorale non è fattibile.
La società prevede anche di presentare ulteriori dati sulla selezione del candidato clinico principale di RTNova al ASCO Annual Meeting a giugno 2025. Questo sviluppo si integra con il lavoro clinico e preclinico esistente di Calidi su viroterapie cellulari localizzate e intratumorali con SNV (SuperNova) e NNV (NeuroNova).
Calidi Biotherapeutics (NYSE: CLDI) anunció la aceptación de su resumen para presentación en la AACR Annual Meeting en Chicago (25-30 de abril de 2025). La presentación, titulada 'Desarrollo de una Viroterapia Sistémica Envolvente para el Enfoque de Todos los Sitios Metastásicos', mostrará datos de su plataforma propietaria RTNova.
La plataforma presenta una nueva cepa de virus vaccinia envuelta con membrana celular humana (virus envuelto extracelular o EEV), diseñada para atacar tumores distantes mientras evita la eliminación por parte del sistema inmunológico. Esta tecnología tiene como objetivo abordar los desafíos de tratamiento en cánceres metastásicos en etapas avanzadas, especialmente cuando no es factible la administración intratumoral.
La empresa también planea enviar datos adicionales sobre la selección de su candidato clínico principal de RTNova en la ASCO Annual Meeting en junio de 2025. Este desarrollo complementa el trabajo clínico y preclínico existente de Calidi sobre viroterapias basadas en células localizadas e intratumorales con SNV (SuperNova) y NNV (NeuroNova).
Calidi Biotherapeutics (NYSE: CLDI)는 시카고에서 개최되는 AACR 연례 회의(2025년 4월 25일-30일)에서 발표할 초록이 수락되었다고 발표했습니다. '모든 전이성 부위를 겨냥한 전신 포장 바이러스를 이용한 치료 개발'이라는 제목의 발표에서는 자사의 독점 플랫폼인 RTNova의 데이터를 소개할 예정입니다.
이 플랫폼은 면역 시스템에 의해 제거되지 않도록 설계된 인간 세포막으로 포장된 새로운 백시니아 바이러스 균주(세포외 포장 바이러스 또는 EEV)를 특징으로 하며, 원거리 종양을 목표로 합니다. 이 기술은 특히 종양 내 투여가 불가능할 때 말기 전이성 암의 치료 도전 과제를 해결하는 것을 목표로 합니다.
회사는 또한 2025년 6월 ASCO 연례 회의에서 RTNova의 주요 임상 후보 선택에 대한 추가 데이터를 제출할 계획입니다. 이 개발은 SNV(슈퍼노바) 및 NNV(뉴로노바)와 함께 Calidi의 기존의 국소 및 종양 내 세포 기반 바이로테라피 관련 임상 및 전임상 작업을 보완합니다.
Calidi Biotherapeutics (NYSE: CLDI) a annoncé l'acceptation de son résumé pour une présentation lors de la AACR Annual Meeting à Chicago (25-30 avril 2025). La présentation, intitulée 'Développement d'une Virothérapie Systémique Enveloppée ciblant Tous les Sites Métastatiques', mettra en avant des données de leur plateforme propriétaire RTNova.
La plateforme dispose d'une souche de virus vaccinia novatrice enveloppée de membrane cellulaire humaine (virus enveloppé extracellulaire ou EEV), conçue pour cibler les tumeurs éloignées tout en évitant l'élimination par le système immunitaire. Cette technologie vise à relever les défis de traitement dans les cancers avancés et métastatiques, en particulier lorsque l'administration intratumorale n'est pas faisable.
L'entreprise prévoit également de soumettre des données supplémentaires sur la sélection de son candidat clinique principal RTNova lors de la ASCO Annual Meeting en juin 2025. Ce développement complète le travail clinique et préclinique existant de Calidi sur les virothérapies cellulaires localisées et intratumorales avec SNV (SuperNova) et NNV (NeuroNova).
Calidi Biotherapeutics (NYSE: CLDI) hat die Annahme seines Abstracts für die Präsentation auf dem AACR Annual Meeting in Chicago (25.-30. April 2025) bekannt gegeben. Die Präsentation mit dem Titel 'Entwicklung einer Systemischen Umhüllten Virotherapie zur gezielten Behandlung aller metastatischen Stellen' wird Daten von ihrer eigenen Plattform RTNova vorstellen.
Die Plattform verfügt über einen neuartigen Vaccinia-Virus-Stamm, der mit menschlicher Zellmembran umhüllt ist (extrazellulärer umhüllter Virus oder EEV), und ist darauf ausgelegt, entfernte Tumoren anzuvisieren, während sie eine Ausschaltung durch das Immunsystem vermeidet. Diese Technologie zielt darauf ab, die Behandlungsherausforderungen bei fortgeschrittenen metastatischen Krebserkrankungen anzugehen, insbesondere wenn eine intratumorale Verabreichung nicht möglich ist.
Das Unternehmen plant auch, zusätzliche Daten zur Auswahl des führenden klinischen Kandidaten von RTNova auf dem ASCO Annual Meeting im Juni 2025 einzureichen. Diese Entwicklung ergänzt die bestehenden klinischen und präklinischen Arbeiten von Calidi zu lokalisierten und intratumoralen zellbasierten Virotherapien mit SNV (SuperNova) und NNV (NeuroNova).
- Development of novel systemic delivery platform (RTNova) targeting multiple metastatic sites
- Technology designed to overcome current treatment barriers in advanced-stage cancers
- Acceptance to present at major industry conference (AACR)
- None.
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that its abstract, titled "Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites", has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting April 25-30, 2025 in Chicago, IL.
This significant milestone reflects Calidi’s ongoing commitment to advancing systemic enveloped virotherapy as a transformative approach to target and kill metastatic cancers, which are the leading cause of cancer-related mortality. The data presented will focus on the development of Calidi's proprietary RTNova systemic platform, showcasing its potential to overcome current barriers in metastatic cancer treatment by enabling targeted systemic delivery to multiple tumor sites without rapid elimination by the body’s immune system.
This systemic platform addresses the challenges of treating advanced-stage metastatic cancers, including lung cancer, when intratumoral administration is not feasible. Calidi designed a novel vaccinia virus strain that is enveloped with a human cell membrane (extracellular enveloped virus or EEV) that offers protection while targeting distant tumors and upon reaching the tumor, induces a robust response from the patient’s immune cells which produces a more durable therapeutic effect.
“Our acceptance to present at AACR underscores the transformative potential of our systemic virotherapy platform,” said Allan Camaisa, CEO and Chairman of Calidi Biotherapeutics. “We are proud to share our pioneering research on the RTNova systemic virotherapy platform, which has the potential to redefine how metastatic cancers are treated and significantly improve outcomes for patients facing advanced-stage disease.”
In addition to the AACR presentation, Calidi plans to submit an abstract to unveil further key data at the ASCO Annual Meeting in June 2025, highlighting its progress toward selecting a lead clinical candidate for RTNova. This work complements Calidi’s ongoing clinical and preclinical efforts in localized and intratumoral cell-based virotherapies with SNV (SuperNova) and NNV (NeuroNova), collectively demonstrating Calidi's approach to revolutionizing cancer treatment.
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies, are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.
Forward-Looking Statements
This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning upcoming key milestones (including the reporting of interim clinical results and the dosing of patients), planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Registration Statements filed with the SEC on (i) Form S-4 filed on August 2, 2023 and the corresponding prospectus filed on August 4, 2023, and (ii) on Form S-1 filed on April 15, 2024, and the Company’s periodic reports filed with the SEC on (i) Form 10-K filed on March 15, 2024, (ii) Form 10-Q filed on May 14, 2024, (iii) Form 10-Q filed on August 13, 2024, and (iv) Form 10-Q filed on November 12, 2024. These reports may be amended or supplemented by other reports we file with the SEC from time to time.
Corporate Communications:
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
CLDI@redchip.com
Source: Calidi Biotherapeutics, Inc.
FAQ
What is Calidi Biotherapeutics' (CLDI) RTNova platform and how does it work?
When will Calidi Biotherapeutics (CLDI) present its RTNova data at AACR 2025?
What types of cancer does Calidi's (CLDI) RTNova platform target?
What are the three main therapeutic platforms being developed by Calidi (CLDI)?
